Ipamorelin · Research brief

What Is IGF-1 Long R3? (Modified Growth Factor)

Q: How does IGF-1 Long R3 differ structurally from native human IGF-1?

IGF-1 Long R3 contains two structural modifications: an arginine-to-glutamic-acid substitution at position 3 (the ‘R3’ mutation) and a 13-amino-acid N-terminal extension derived from the insulin B-domain. These changes reduce binding affinity to IGF binding proteins by approximately 100-fold while preserving 80–90% of IGF-1 receptor binding affinity. The result is a compound that remains bioavailable and active for 20–30 hours in vitro compared to 5–10 minutes for unmodified IGF-1, which is rapidly sequestered by IGFBP-3.

Q: Can IGF-1 Long R3 be used in serum-containing cell culture media?

Yes, and this is one of its primary advantages over native IGF-1. Standard cell culture media supplemented with fetal bovine serum contains endogenous IGF binding proteins that sequester and inactivate native IGF-1 within the first hour, reducing effective concentration by 70–90%. IGF-1 Long R3’s structural modifications prevent IGFBP binding, allowing it to remain bioavailable even in high-serum conditions. This makes it suitable for protocols where serum-free media would compromise cell viability or introduce confounding metabolic stress.

Q: What is the recommended storage protocol for reconstituted IGF-1 Long R3?

Store lyophilized IGF-1 Long R3 powder at −20°C with desiccant protection until reconstitution. Once reconstituted with sterile bacteriostatic water, store the solution at 2–8°C and use within 14 days to maintain bioactivity. Avoid freeze-thaw cycles—aliquot the reconstituted peptide into single-use volumes if repeated access is required. Temperature excursions above 8°C cause irreversible protein aggregation and loss of receptor binding activity. The reconstituted solution should be clear and colorless; any cloudiness or particulate formation indicates degradation and the vial should be discarded.

Q: How much more potent is IGF-1 Long R3 compared to native IGF-1 in cell culture?

IGF-1 Long R3 produces approximately 2–3 times greater cumulative cellular response than equimolar native IGF-1 over 24–48 hour observation periods, primarily due to sustained bioavailability rather than increased receptor affinity. While its intrinsic IGF-1 receptor binding affinity is slightly lower (80–90% of native), the absence of binding protein sequestration means more molecules remain free to engage receptors. In practical terms, 30–50 ng/mL IGF-1 Long R3 dosed once per 24 hours produces biological responses equivalent to 100 ng/mL native IGF-1 dosed every 4–6 hours in most proliferation and differentiation assays.

Q: What signaling pathways does IGF-1 Long R3 activate?

IGF-1 Long R3 activates the IGF-1 receptor, triggering two primary downstream cascades: the PI3K/Akt/mTOR pathway, which drives protein synthesis, glucose uptake, glycogen synthesis, and anti-apoptotic signaling, and the MAPK/ERK pathway, which regulates cell proliferation and differentiation. Akt phosphorylates and inactivates TSC2, disinhibiting mTORC1—the master regulator of ribosomal biogenesis and translation. At supra-physiological concentrations (>100 nM), IGF-1 Long R3 also exhibits cross-reactivity with the insulin receptor, particularly hybrid insulin receptor/IGF-1 receptors found in metabolic tissues, though this represents off-target activity in most research contexts.

Real Peptides Research TeamEditorial

Updated March 26, 20269 min read

48 WORDS

Short answer

Key takeaways

IGF-1 Long R3 is an 83-amino-acid synthetic analog of human IGF-1 with two structural modifications that reduce binding protein affinity by approximately 100-fold and extend half-life from minutes to 20–30 hours in vitro.
The arginine-to-glutamic-acid substitution at position 3 and the 13-amino-acid N-terminal extension prevent sequestration by IGFBPs, particularly IGFBP-3, which normally binds and inactivates over 90% of circulating native IGF-1.
IGF-1 Long R3 activates the IGF-1 receptor with approximately 80–90% of native IGF-1's binding affinity but produces 2–3 times greater cumulative cellular response due to sustained bioavailability and receptor occupancy lasting 48–72 hours.
The compound drives downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, promoting protein synthesis, cell proliferation, differentiation, and metabolic reprogramming across multiple cell division cycles.
IGF-1 Long R3 maintains bioactivity in serum-containing culture conditions where native IGF-1 is rapidly sequestered, making it suitable for protocols that cannot tolerate serum-free media.
Research applications include myoblast differentiation studies, hepatocyte proliferation models, neural stem cell culture, metabolic flux analysis, and any protocol requiring sustained growth factor signaling without repeated dosing.

When researchers need sustained growth factor signaling that standard IGF-1 can't provide, they turn to a modified analog that stays active orders of magnitude longer. IGF-1 Long R3 was engineered specifically to overcome the biggest limitation of endogenous insulin-like growth factor: binding proteins that neutralize it almost instantly. The difference isn't incremental—it's the gap between a compound that degrades in under ten minutes and one that maintains bioactivity for days.

We've supplied research-grade peptides to laboratories conducting growth factor studies for years. The gap between theoretical mechanism and practical experimental design comes down to stability, purity, and dosing precision—factors that separate publishable data from inconclusive trials.

What is IGF-1 Long R3?

IGF-1 Long R3 is a synthetic 83-amino-acid analog of human insulin-like growth factor-1 (IGF-1) with two key structural modifications: substitution of glutamic acid for arginine at position 3 (the 'R3' designation) and a 13-amino-acid N-terminal extension. These changes dramatically reduce binding affinity to IGF binding proteins (IGFBPs), particularly IGFBP-3, which normally sequester and inactivate native IGF-1 within 5–10 minutes of secretion. The result is a compound with approximately three times the potency and a half-life extended from minutes to 20–30 hours in vitro.

The Structural Modifications That Define IGF-1 Long R3

Native human IGF-1 contains 70 amino acids arranged in a structure remarkably similar to insulin, which explains its dual metabolic and anabolic signaling capacity. But that structural homology to insulin comes with a regulatory mechanism: six distinct IGF binding proteins (IGFBP-1 through IGFBP-6) that circulate in serum and bind IGF-1 with higher affinity than the IGF-1 receptor itself. IGFBP-3 alone accounts for 80–90% of circulating IGF-1 binding, effectively creating a reservoir that releases IGF-1 in tightly controlled pulses. This regulatory system works beautifully for endocrine homeostasis—and terribly for experimental protocols requiring sustained receptor activation.

IGF-1 Long R3 disrupts this binding dynamic through two modifications. The arginine-to-glutamic-acid substitution at position 3 creates an electrostatic repulsion that reduces IGFBP affinity by approximately 100-fold. The 13-amino-acid N-terminal extension—derived from the B-domain of insulin—further sterically hinders binding protein interaction while leaving IGF-1 receptor binding largely intact. The receptor binding affinity of IGF-1 Long R3 is approximately 80–90% that of native IGF-1, but because it remains unbound and bioavailable, the net cellular response is substantially greater. Published kinetic studies using radiolabeled IGF-1 Long R3 demonstrate sustained receptor occupancy 48–72 hours post-administration in cell culture models, compared to less than 30 minutes for unmodified IGF-1.

The practical consequence: researchers can administer IGF-1 Long R3 once and observe growth factor signaling across multiple cell division cycles, enabling studies of differentiation, hypertrophy, and metabolic reprogramming that native IGF-1's rapid clearance makes impractical. The extended half-life also reduces experimental variance caused by pulsatile clearance, a critical consideration for dose-response studies and mechanistic pathway mapping.

Mechanism of Action: Receptor Binding and Downstream Signaling

IGF-1 Long R3 exerts its biological effects primarily through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase expressed ubiquitously across mammalian cell types. Upon ligand binding, IGF-1R undergoes autophosphorylation at multiple tyrosine residues in its intracellular domain, creating docking sites for adaptor proteins including insulin receptor substrate-1 (IRS-1) and Shc. These adaptors propagate signal through two primary pathways: the PI3K/Akt/mTOR axis, which drives protein synthesis, glucose uptake, and cell survival, and the MAPK/ERK cascade, which regulates proliferation and differentiation.

The PI3K/Akt pathway is particularly relevant to growth factor research. Akt activation phosphorylates and inactivates GSK-3β, relieving its inhibition of glycogen synthase and shifting metabolism toward anabolic processes. Akt also phosphorylates tuberous sclerosis complex 2 (TSC2), disinhibiting mTORC1—the master regulator of ribosomal biogenesis and cap-dependent translation. This is the mechanism underlying IGF-1's role in muscle hypertrophy, hepatocyte proliferation, and neural progenitor expansion. In the absence of binding protein sequestration, IGF-1 Long R3 sustains mTORC1 activation at levels 2–3 times higher than equimolar native IGF-1 over 24-hour observation windows.

The compound also exhibits modest cross-reactivity with the insulin receptor, particularly the hybrid insulin receptor/IGF-1 receptor found in metabolic tissues. At concentrations above 100 nM, IGF-1 Long R3 can activate insulin receptor substrate pathways and promote glucose transporter translocation, though this represents off-target activity in most research contexts. Selectivity for IGF-1R over insulin receptor is approximately 10:1, compared to 50:1 for native IGF-1—a tradeoff accepted for the pharmacokinetic advantages.

Our IGF 1 LR3 is synthesized through solid-phase peptide assembly with exact amino-acid sequencing verified by mass spectrometry, ensuring the structural integrity required for reproducible receptor binding kinetics. Batch-to-batch consistency in IGF-1 Long R3 purity directly determines whether dose-response curves replicate across experimental runs.

IGF-1 Long R3 vs Native IGF-1: Performance in Research Models

The functional differences between IGF-1 Long R3 and endogenous IGF-1 become most apparent in time-course experiments. When primary myoblasts are exposed to 50 ng/mL native IGF-1, phosphorylated Akt levels peak within 15 minutes and return to baseline by 90 minutes. The same concentration of IGF-1 Long R3 produces a sustained elevation in phospho-Akt for 12–16 hours. This isn't simply longer activity—it's a qualitatively different experimental capability that enables researchers to separate acute signaling events from chronic adaptive responses.

In hepatocyte culture models, IGF-1 Long R3 drives cumulative protein synthesis rates 40–60% higher than native IGF-1 over 48-hour incubations despite identical molar dosing. The mechanism is straightforward: native IGF-1 must be supplemented continuously or re-dosed every 4–6 hours to maintain receptor occupancy, introducing handling variability and stress artifacts. IGF-1 Long R3 maintains therapeutic levels through a single addition, reducing confounding variables and experimental noise. Published studies in Journal of Biological Chemistry and Endocrinology have consistently demonstrated 2–3 fold greater cumulative cellular response to IGF-1 Long R3 in proliferation assays, differentiation protocols, and metabolic flux studies.

The resistance to binding protein degradation also matters in serum-containing culture conditions. Standard cell culture media supplemented with 10% fetal bovine serum contains endogenous IGFBPs that rapidly sequester exogenous IGF-1, reducing effective concentration by 70–90% within the first hour. IGF-1 Long R3 remains largely unbound even in high-serum conditions, making it the preferred analog for experiments that cannot use serum-free media without compromising cell viability.

Comparison: IGF-1 Analogs and Growth Factors in Research

The choice of growth factor analog determines the entire experimental design—duration, dosing frequency, and which biological processes can be meaningfully isolated.

Factor	Half-Life	IGFBP Binding Affinity	Primary Use Case	Dosing Frequency	Professional Assessment
Native IGF-1	5–10 minutes (in vitro)	High (>90% bound)	Acute signaling studies, brief receptor activation	Every 4–6 hours	Required for protocols modeling physiological pulsatile release; impractical for sustained signaling studies
IGF-1 Long R3	20–30 hours (in vitro)	Minimal (<10% bound)	Differentiation, hypertrophy, multi-day protocols	Once per 24–48 hours	Gold standard for sustained growth factor exposure with minimal experimental handling
Des(1-3)IGF-1	15–30 minutes	Reduced vs native	High-potency short-duration studies	Every 6–8 hours	10× more potent than native IGF-1 but still binding-protein-sensitive; niche use in receptor affinity studies
Insulin	4–6 minutes (in vitro)	None (different binding protein family)	Metabolic signaling, glucose uptake, receptor cross-reactivity controls	Every 2–4 hours	Metabolic focus rather than growth; used when IGF-1R/insulin receptor signaling overlap must be distinguished
MK 677 (oral ghrelin mimetic)	4–6 hours (oral bioavailability)	N/A (stimulates endogenous IGF-1 release)	Models of endogenous growth hormone/IGF-1 axis stimulation	Once daily	Indirect IGF-1 elevation through GH secretagogue pathway; useful for systemic models but not cell culture

For protocols requiring uninterrupted growth factor signaling across 48–96 hours—common in stem cell differentiation, organoid culture, and chronic metabolic reprogramming studies—IGF-1 Long R3 eliminates the repeated handling and media supplementation that introduce mechanical stress and experimental drift.

What If: IGF-1 Long R3 Scenarios

What If the Reconstituted Peptide Appears Cloudy or Contains Visible Particles?

Discard the vial immediately and do not use it. Particulate formation or cloudiness indicates protein aggregation, denaturation, or contamination—all of which compromise bioactivity and experimental validity. IGF-1 Long R3 reconstituted in sterile bacteriostatic water should produce a clear, colorless solution. Aggregates form when peptides are exposed to temperature excursions, freeze-thaw cycles, or incompatible reconstitution buffers. Using compromised peptide introduces uncontrolled variables that invalidate dose-response data and mechanistic conclusions. Proper storage—lyophilized powder at −20°C, reconstituted solution at 2–8°C for no more than 14 days—prevents degradation under standard laboratory conditions.

What If You Need to Compare IGF-1 Long R3 Results to Published Studies Using Native IGF-1?

Account for the potency difference explicitly in your dosing calculations and experimental timeline. If a published protocol used 100 ng/mL native IGF-1 dosed every 6 hours, the molar-equivalent starting point for IGF-1 Long R3 is approximately 30–50 ng/mL dosed once per 24 hours, adjusted for the 2–3 fold greater cumulative response observed in most cellular models. Direct concentration matching without accounting for binding protein resistance will produce supra-physiological signaling and skew downstream pathway activation. Include dose-titration pilot studies to establish equivalent biological endpoints—such as matching peak phospho-Akt levels or equivalent cumulative protein synthesis rates—before committing to full experimental runs.

What If the Cell Line You're Using Shows Minimal Response to IGF-1 Long R3?

Verify IGF-1 receptor expression first—some immortalized cell lines downregulate IGF-1R during passage or under specific culture conditions. Western blot for IGF-1R or flow cytometry quantification establishes whether the receptor is present at sufficient density to mediate signaling. If IGF-1R expression is confirmed, evaluate competing signaling inputs: high insulin concentrations in culture media can saturate hybrid insulin receptor/IGF-1 receptors, and constitutive PI3K/Akt activation from oncogenic mutations can mask IGF-1-driven pathway modulation. Serum-free conditions with defined insulin concentrations (typically ≤10 nM) provide cleaner IGF-1 Long R3 dose-response curves by minimizing receptor competition and baseline pathway activation.

What If Your Protocol Requires Pulsatile Rather Than Sustained IGF-1 Signaling?

Use native IGF-1 or Des(1-3)IGF-1 instead—IGF-1 Long R3's extended half-life makes it unsuitable for modeling physiological pulsatile release patterns that characterize endogenous growth hormone/IGF-1 axis dynamics. Circadian and ultradian IGF-1 pulses, driven by pulsatile GH secretion, are a critical regulatory feature in vivo. Protocols studying receptor desensitization, feedback inhibition, or time-of-day-dependent pathway sensitivity require growth factors that clear rapidly enough to create distinct on/off signaling windows. IGF-1 Long R3's sustained receptor occupancy flattens this temporal structure, making it the wrong tool for those specific research questions despite its advantages in differentiation and hypertrophy studies.

The Engineered Truth About IGF-1 Long R3

Here's the engineered truth: IGF-1 Long R3 was not designed to mimic physiological IGF-1 signaling—it was designed to circumvent it. The binding proteins that IGF-1 Long R3 evades exist precisely to prevent the kind of sustained, unregulated receptor activation this analog delivers. In vivo, that regulatory system prevents uncontrolled growth, manages insulin sensitivity, and coordinates growth factor availability with nutritional state. IGF-1 Long R3 strips that regulation away entirely, which is exactly what makes it valuable for research and exactly what makes it inappropriate outside controlled experimental contexts. The same modification that enables clean, reproducible dose-response curves in cell culture would produce unpredictable systemic effects in whole organisms. It is a tool purpose-built for mechanistic studies, not a molecule designed for therapeutic use.

IGF-1 Long R3 was originally developed in the 1990s by GroPep Bioreagents (now part of Merck) specifically as a research reagent for cell culture applications. It has never been approved for human or veterinary therapeutic use, and its pharmacokinetics, tissue distribution, and long-term safety profile in living systems remain largely uncharacterized outside of limited animal model studies. The extended bioavailability that researchers value in vitro translates to prolonged systemic exposure and potential off-target effects in vivo, including hypoglycemia risk from insulin receptor cross-reactivity and uncontrolled mitogenic signaling in tissues expressing IGF-1R.

For researchers designing experiments requiring sustained growth factor input—differentiation protocols, organoid expansion, chronic metabolic reprogramming studies—IGF-1 Long R3 remains the most reliable tool available. The key is recognizing what it models: continuous maximal stimulation of the IGF-1 receptor pathway, not the pulsatile, feedback-regulated signaling that characterizes endogenous IGF-1 biology.

If the scientific question involves sustained pathway activation, IGF-1 Long R3 delivers unmatched experimental control—just recognize that the very modifications that make it experimentally useful also make it a poor proxy for understanding normal physiology. Every research-grade peptide we supply, including CJC1295 Ipamorelin for growth hormone secretagogue studies and Ipamorelin for selective ghrelin receptor work, is selected and batch-verified for the specific experimental context it serves. The compound's suitability depends entirely on whether the research question requires sustained signaling or physiological accuracy—and IGF-1 Long R3 was engineered unambiguously for the former.

Questions

IGF-1 Long R3 contains two structural modifications: an arginine-to-glutamic-acid substitution at position 3 (the ‘R3’ mutation) and a 13-amino-acid N-terminal extension derived from the insulin B-domain. These changes reduce binding affinity to IGF binding proteins by approximately 100-fold while preserving 80–90% of IGF-1 receptor binding affinity. The result is a compound that remains bioavailable and active for 20–30 hours in vitro compared to 5–10 minutes for unmodified IGF-1, which is rapidly sequestered by IGFBP-3.

Yes, and this is one of its primary advantages over native IGF-1. Standard cell culture media supplemented with fetal bovine serum contains endogenous IGF binding proteins that sequester and inactivate native IGF-1 within the first hour, reducing effective concentration by 70–90%. IGF-1 Long R3’s structural modifications prevent IGFBP binding, allowing it to remain bioavailable even in high-serum conditions. This makes it suitable for protocols where serum-free media would compromise cell viability or introduce confounding metabolic stress.

Store lyophilized IGF-1 Long R3 powder at −20°C with desiccant protection until reconstitution. Once reconstituted with sterile bacteriostatic water, store the solution at 2–8°C and use within 14 days to maintain bioactivity. Avoid freeze-thaw cycles—aliquot the reconstituted peptide into single-use volumes if repeated access is required. Temperature excursions above 8°C cause irreversible protein aggregation and loss of receptor binding activity. The reconstituted solution should be clear and colorless; any cloudiness or particulate formation indicates degradation and the vial should be discarded.

IGF-1 Long R3 produces approximately 2–3 times greater cumulative cellular response than equimolar native IGF-1 over 24–48 hour observation periods, primarily due to sustained bioavailability rather than increased receptor affinity. While its intrinsic IGF-1 receptor binding affinity is slightly lower (80–90% of native), the absence of binding protein sequestration means more molecules remain free to engage receptors. In practical terms, 30–50 ng/mL IGF-1 Long R3 dosed once per 24 hours produces biological responses equivalent to 100 ng/mL native IGF-1 dosed every 4–6 hours in most proliferation and differentiation assays.

IGF-1 Long R3 activates the IGF-1 receptor, triggering two primary downstream cascades: the PI3K/Akt/mTOR pathway, which drives protein synthesis, glucose uptake, glycogen synthesis, and anti-apoptotic signaling, and the MAPK/ERK pathway, which regulates cell proliferation and differentiation. Akt phosphorylates and inactivates TSC2, disinhibiting mTORC1—the master regulator of ribosomal biogenesis and translation. At supra-physiological concentrations (>100 nM), IGF-1 Long R3 also exhibits cross-reactivity with the insulin receptor, particularly hybrid insulin receptor/IGF-1 receptors found in metabolic tissues, though this represents off-target activity in most research contexts.

Differentiation protocols—myoblast fusion, adipogenesis, chondrogenesis, neural progenitor commitment—typically span 48–96 hours and require continuous growth factor signaling throughout multiple cell division cycles. Native IGF-1’s rapid clearance (half-life of 5–10 minutes) necessitates dosing every 4–6 hours or continuous perfusion, both of which introduce mechanical stress, handling variability, and experimental drift. IGF-1 Long R3’s extended half-life (20–30 hours) allows a single dose to maintain therapeutic receptor occupancy across the entire differentiation window, reducing confounding variables and enabling cleaner isolation of growth factor effects from culture handling artifacts.

Yes, at concentrations above 100 nM, IGF-1 Long R3 exhibits modest insulin receptor cross-reactivity, particularly with hybrid insulin receptor/IGF-1 receptors expressed in liver, muscle, and adipose tissue. Selectivity for IGF-1R over insulin receptor is approximately 10:1, compared to 50:1 for native IGF-1. This represents a tradeoff accepted for the pharmacokinetic advantages—the structural modifications that prevent IGFBP binding also slightly reduce receptor selectivity. In most cell culture applications using 10–100 nM concentrations, IGF-1R activation predominates, but metabolic studies using higher doses must account for potential insulin receptor-mediated glucose uptake and lipogenesis.

Most published protocols use IGF-1 Long R3 at 10–100 ng/mL (approximately 1.3–13 nM), with 50 ng/mL representing a common starting point for proliferation and differentiation studies. Dose-response studies typically span 1–200 ng/mL to establish EC50 values for specific endpoints such as Akt phosphorylation, protein synthesis rate, or cell cycle progression. The optimal concentration depends on cell type, IGF-1 receptor expression density, and experimental endpoint—myoblast differentiation protocols often use 50–100 ng/mL, while neural stem cell expansion may require only 10–25 ng/mL to avoid excessive proliferation at the expense of differentiation capacity.

IGF-1 Long R3 has been used in limited animal model studies, but its prolonged systemic half-life, incomplete pharmacokinetic characterization, and potential off-target effects make it a poor choice for most in vivo applications. The extended bioavailability that is advantageous in cell culture translates to sustained systemic exposure, hypoglycemia risk from insulin receptor cross-reactivity, and uncontrolled mitogenic signaling in IGF-1R-expressing tissues. Native IGF-1 or tissue-specific conditional expression models provide more physiologically relevant tools for in vivo growth factor research. IGF-1 Long R3 remains primarily a cell culture reagent optimized for sustained receptor activation in controlled in vitro environments.

Start with approximately one-third the molar concentration of native IGF-1 and extend the dosing interval from every 4–6 hours to once per 24 hours. For example, if a protocol used 100 ng/mL native IGF-1 every 6 hours, begin with 30–50 ng/mL IGF-1 Long R3 dosed once daily and titrate based on biological endpoint measurements—phospho-Akt levels, proliferation rate, or differentiation marker expression. The goal is to match cumulative pathway activation rather than peak signal intensity, which requires dose-titration pilot studies to account for differences in cell type sensitivity, serum composition, and receptor expression density across experimental systems.

Verify peptide purity by HPLC (minimum 95% for research-grade material), confirm molecular weight and amino-acid sequence by mass spectrometry, and request third-party endotoxin testing (≤1.0 EU/mg for cell culture applications). Batch-to-batch consistency in these parameters determines whether dose-response curves replicate across experimental runs. Certificate of analysis documentation should include reconstitution protocols, storage stability data, and sterility verification. Lyophilized peptides shipped without cold chain integrity or stored above −20°C prior to reconstitution may show normal appearance but compromised bioactivity—source from suppliers who provide full chain-of-custody documentation and analytical verification for every batch.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA